newsfilter
← Latest News
GlobeNewswire·

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational